Liraglutide vs AOD-9604.

Liraglutide is a long-acting, injectable glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated analog of the human incretin hormone GLP-1. It is roughly 97% homologous to native GLP-1, differing by an arginine-for-lysine substitution at position 34 and a C16 palmitic-acid chain attached via a glutamic-acid spacer at lysine 26. That fatty-acid acylation promotes reversible binding to serum albumin and self-association, slowing degradation and renal clearance enough to extend its action to once-daily dosing. It is marketed by Novo Nordisk as Victoza (type 2 diabetes) and Saxenda (chronic weight management), and is now also available as an FDA-approved generic.

AOD-9604 ("Advanced Obesity Drug 9604") is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic region of human growth hormone (hGH), residues 177–191, with an added tyrosine at the N-terminus. It was engineered in the 1990s by researchers at Monash University and developed by the Australian biotech Metabolic Pharmaceuticals as an orally-investigated anti-obesity agent. The design goal was to isolate hGH's fat-mobilizing activity while leaving out the growth-promoting, IGF-1-stimulating actions of the full hormone.

Liraglutide binds and activates the GLP-1 receptor, a Gs-protein-coupled receptor that raises intracellular cyclic AMP. In pancreatic beta cells this potentiates glucose-dependent insulin secretion, meaning insulin release is amplified mainly when blood glucose is elevated; it also suppresses inappropriately high glucagon secretion from alpha cells, which together improve postprandial and fasting glucose. Because the effect is glucose-dependent, GLP-1 agonism carries low intrinsic hypoglycemia risk as monotherapy. Liraglutide additionally slows gastric emptying and acts on hypothalamic appetite circuits to increase satiety and reduce food intake, the basis for its weight-lowering effect.

In rodent models, AOD-9604 reproduces the lipolytic (fat-breakdown) and fat-oxidation–promoting effects of full-length growth hormone without binding the GH receptor and without raising IGF-1. Mechanistic work in obese and beta-3-adrenergic-receptor knockout mice indicated its effect on fat metabolism is associated with modulation of beta-3 adrenergic receptor activity and increased lipolysis and fat oxidation rather than classic GH-receptor signaling. Because it does not engage the GH receptor, it was hypothesized to avoid the insulin-resistance and tissue-growth liabilities of GH itself. Importantly, the cleanly receptor-independent, IGF-1-sparing profile is best characterized in animal and in-vitro work, not firmly established in humans.

Human evidence for liraglutide is extensive and high-quality, not preclinical extrapolation. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; n=9,340 with type 2 diabetes at high cardiovascular risk, median 3.8-year follow-up) found a lower rate of the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke versus placebo, plus lower cardiovascular and all-cause mortality; its design was prespecified (Marso et al., Am Heart J 2013). For obesity, the 56-week SCALE trial in adults without diabetes (Pi-Sunyer et al., NEJM 2015; n=3,731) showed significantly greater weight loss with liraglutide 3.0 mg plus lifestyle than with placebo plus lifestyle. Liraglutide has also been studied in adolescents with obesity and in prediabetes. The main human gaps now are comparative: newer agents such as semaglutide and tirzepatide produce larger weight reductions in head-to-head and cross-trial comparisons, and liraglutide's once-daily injection is a practical disadvantage.

Preclinical evidence is the strongest part of the AOD-9604 record: chronic dosing reduced body-weight gain and increased fat oxidation in obese mice (Heffernan et al., Int J Obes, 2001; PMID 11673763). It progressed into human obesity trials in the early-mid 2000s; a 12-week randomized study reported only a modest separation from placebo (on the order of ~1–2 kg), and development was halted around 2007 after a larger ~24-week trial failed to show meaningful weight-loss efficacy, particularly once diet and exercise were standardized. No peer-reviewed pivotal trial demonstrates clinically useful weight loss, and there is no robust human evidence for the commonly marketed claims around cartilage, joint, or tendon repair: those rest on limited preclinical/early work. In short, the human data are negative-to-thin for obesity and largely absent for other indications.

The most common documented adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually dose-related and most pronounced early in treatment. Labeled warnings include acute pancreatitis, acute gallbladder disease (cholelithiasis/cholecystitis), acute kidney injury (often in the setting of dehydration from GI losses), and increased heart rate; in glucose-lowering combinations with insulin or sulfonylureas, hypoglycemia risk rises. Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent medullary thyroid carcinoma findings, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2; whether this risk translates to humans remains unresolved. Long-term safety in non-medical, non-prescribed "research" use is uncharacterized, and unregulated/compounded sources add contamination and mislabeling risks.

Across the obesity trials, AOD-9604 was generally reported as well tolerated with a clean short-term safety signal, which is part of why it was later nominated for compounding review; however, these data come from time-limited studies and do not establish long-term safety. There is no established safety profile for chronic use, for injectable research-grade ("gray market") product, or for the unindicated cosmetic, joint, and anti-aging uses now marketed online. Purity, identity, and contamination of non-pharmaceutical material are real concerns, underscored by published forensic identification of illicit AOD9604 preparations (Drug Testing and Analysis, 2014; PMID 24976118). No dosing or administration guidance is provided here.

FDA-approved: as Victoza (2010) for type 2 diabetes in adults and later adolescents, and as Saxenda (2014) for chronic weight management; a generic liraglutide injection has since been approved. It is a legitimately prescribed medication, not a research-only compound, and is not a banned substance under standard anti-doping frameworks the way some hormones are.

AOD-9604 is not approved by the FDA (or any major regulator) for any therapeutic use; its obesity development program was discontinued, and it remains investigational/research-use-only. The FDA has evaluated it among nominated bulk drug substances for pharmacy compounding under section 503A and has flagged peptide candidates of this type as raising significant safety questions; it is also prohibited in sport and tested for by anti-doping authorities under the WADA framework.